CTLA4 and melanoma: Furthermore, triple combination therapy, which includes the CSC-DC vaccine and PD1 and CTLA-4 blockade, has been shown to enhance the T-cell response against CSCs and reduce TGF-β secretion in melanoma mouse models [268].